Vivo Capital and Biotech

Selected healthcare news for the capital firm - Vivo Capital, and the healthcare topic - Biotech. We have 29 shared news items for this connection to-date. Based on the volume of shared news, it's source, placement and other factors, this connection is scored as strong.  Vivo Capital shares healthcare news with Preventice, Preventice Solutions, Biotech, OrbiMed and dozens of others. Biotech shares news with COVID-19, Pfizer, Food and Drug Administration, Novartis, Merck and hundreds of others.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/20/2021 Chinese Biotech Firm VISEN Raises $150m Led by Sequoia Capital China Home Financial Chinese Biotech Firm VISEN Raises $150m Led by Sequoia Capital China Chinese Biotech Firm VISEN Raises $150m Led by Sequoia Capital China January 20, 2021 Shanghai-based endocrine therapy developer VISEN Pharmaceuticals has ... and CDG Capital. Existing backers Ascendis Pharma, Sofinnova Investments and Vivo Capital also re-upped in the round. The three investors jointly set up VISEN in 2018. Since its inception, the firm claims to be ...
1/13/2021 IO Biotech Completes ‚Ǩ127M Series B Financing By FinSMEsIO Biotech , a Copenhagen, Denmark-based clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win¬Æ technology, raised ‚C¨127m in Series B financing.The round was led by HBM Healthcare Investments, and other new investors joining the round included Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners, PFM Health Sciences, Soleus Capital, Eir Ventures ...
1/11/2021 VISEN Pharmaceuticals closes $150 million Series B financing ... biotech company focussed on developing and commercialising innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced the closing of a $150 million Series B financing.The round was led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma, Vivo Capital ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China SHANGHAI , Jan. 9, 2021 /PRNewswire/ ‚Ai VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China , announced today the closing of a ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China | Markets Insider Business Insider SHANGHAI , Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China , announced today the closing of a $150 ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China ... of its Innovative Endocrinology Therapies in Greater China VISEN Pharmaceuticals 2021-01-09 11:06 3146 Share:SHANGHAI , Jan. 9, VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China ... Innovative Endocrinology Therapies in Greater China PR Newswire - Stock Market NewsSHANGHAI , Jan . 9, 2021 / PRNewswire / ‚Ai VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
1/9/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China Ascendis Pharma A/S Announces Equity Investment in VISEN PharmaceuticalsSHANGHAI , Jan. 9, 2021 /PRNewswire/ ‚Ai VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
1/9/2021 The Ridgway Record SHANGHAI , Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China , announced today the closing of a $150 ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
1/8/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China - GuruFocus.com PR NewswireSHANGHAI, Jan. 9, 2021SHANGHAI , Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China , announced ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
1/8/2021 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China | Ask.com - What's Your Question? SHANGHAI , Jan. 9, VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China , announced today the closing of a $150 million Series ... all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class ...
7/9/2020 Tranquis debuts with $30M for immune cell approach to neurodegenerative diseases | FierceBiotech FierceBiotech ... Vivo Capital, Hillsborough Venture and Correlation Ventures, will bankroll the preclinical development of Tranquis’ lead program and expand its platform and pipeline. “We’re focused on a novel approach that targets myeloid immune cell dysfunction,” Tranquis CEO Sanjay Kakkar, M.D., told Fierce Biotech, referring to a type of immune cell found in the brain and the peripheral nervous system. RELATED: Athira reels in $85M for phase 2/3 Alzheimer's study “In the ...
7/9/2020 Tranquis debuts with $30M for immune cell approach to neurodegenerative diseases | FierceBiotech FierceBiotech ... Vivo Capital, Hillsborough Venture and Correlation Ventures, will bankroll the preclinical development of Tranquis’ lead program and expand its platform and pipeline. “We’re focused on a novel approach that targets myeloid immune cell dysfunction,” Tranquis CEO Sanjay Kakkar, M.D., told Fierce Biotech, referring to a type of immune cell found in the brain and the peripheral nervous system. RELATED: Athira reels in $85M for phase 2/3 Alzheimer's study “In the ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Vivo Capital, according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma, and multiple myeloma in various stages of clinical trials, according to the company. It's working with Johnson & Johnson's subsidiary Janssen on a cell therapy for multiple myeloma. The treatment recently won an expedited approval ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Vivo Capital, according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma, and multiple myeloma in various stages of clinical trials, according to the company. It's working with Johnson & Johnson's subsidiary Janssen on a cell therapy for multiple myeloma. The treatment recently won an expedited approval ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Vivo Capital, according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma, and multiple myeloma in various stages of clinical trials, according to the company. It's working with Johnson & Johnson's subsidiary Janssen on a cell therapy for multiple myeloma. The treatment recently won an expedited approval ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Vivo Capital, according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma, and multiple myeloma in various stages of clinical trials, according to the company. It's working with Johnson & Johnson's subsidiary Janssen on a cell therapy for multiple myeloma. The treatment recently won an expedited approval ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Vivo Capital, according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma, and multiple myeloma in various stages of clinical trials, according to the company. It's working with Johnson & Johnson's subsidiary Janssen on a cell therapy for multiple myeloma. The treatment recently won an expedited approval ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Vivo Capital, according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma, and multiple myeloma in various stages of clinical trials, according to the company. It's working with Johnson & Johnson's subsidiary Janssen on a cell therapy for multiple myeloma. The treatment recently won an expedited approval ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Vivo Capital, according to a recent announcement . It plans to spend the funds on research and development as well as expanding facilities. A subsidiary of GenScript Biotech , Legend has treatments for pancreatic cancer, non-hodgkin lymphoma, and multiple myeloma in various stages of clinical trials, according to the company. It's working with Johnson & Johnson's subsidiary Janssen on a cell therapy for multiple myeloma. The treatment recently won an expedited approval ...
4/1/2020 GenScript Biotech Reports 2019 Financial Results and Provides Business Update PR Newswire NANJING , China , March 31, 2020 /PRNewswire/ -- GenScript Biotech Corp. (Stock Code: 1548.HK), a leading global biotechnology company, yesterday reported full year 2019 financial results and provided a corporate update. In 2019, overall revenue of ... and Lily Asia Ventures, other participating investors included Capital Group, Vivo Capital, and RA Capital. These pre-IPO investors can also choose to invest more into Legend at the IPO stage. This is endorsement for ...
11/26/2019 Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors PR Newswire ... a BComm and an LL.B. from the University of Alberta . Gaurav Aggarwal , M.D., has served as a Managing Director of Vivo Capital LLC, a healthcare focused investment firm, since October 2016 , where he focuses on ... Capital since February 2016 where he focuses on investments in biotechnology companies. From September 2014 to February 2016 , Dr. Richardson served as a Public Equities Analyst at HealthCor Management where he managed small and mid ...
11/7/2019 TOT BIOPHARM (1875.HK) Proceeded with IPO raising over HK$500 million PR Newswire ... its subsidiaries, the "Group", stock code: 1875) was well received by the capital market and should be the eleventh 18A Biotech company listed in Hong Kong since the inception of the new listing regulation last ... Company has great support from several reputable investors such as Vivo Capital and Advantech Capital. Ms. Yeh-Huang Chun-Ying , Executive Director and General Manager of TOT BIOPHARM said, "Since the inception of TOT BIOPHARM ...
10/8/2019 Bolt Biotherapeutics Announces Scientific Advisory Board with the Appointment of Drs. Larry Fong, Roy Herbst and Bruce Roth PR Newswire REDWOOD CITY, Calif. Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, today announced the addition of three world-class researchers to its Scientific Advisory ... by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com where you will find complete biographies of Bolt's SAB ...
9/18/2019 IGM Biosciences goes public PE Hub ... biotech firm focused on developing engineered IgM antibodies for therapeutic use, has raised about $175 million for its IPO of nearly 11 million shares at $16 per share. The stock began trading September 18, 2019 on the NASDAQ under the ticker symbol “IGMS.” The lead underwriters are Jefferies, Piper Jaffray, Stifel and Guggenheim Securities . IGM’s pre-IPO backers include Redmile Group, Janus Henderson Investors and Vivo Capital. PRESS RELEASE MOUNTAIN ...